If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() PsychogeriatricsVolume 3 Issue 1, Pages 39 - 44 Published Online: 6 May 2003 Journal compilation © 2009 The Japanese Psychogeriatric Society The Official Journal of the Japanese Psychogeriatric Society
Abstract | References | Full Text: HTML, PDF (Size: 152K) | Related Articles | Citation Tracking CASE REPORT Effects of low-dose quetiapine on psychotic symptoms in elderly patients with physical illnesses: Report of eight cases Copyright 2003 Japanese Psychogeriatric Society KEYWORDS delirium • elderly • hallucination • quetiapine ABSTRACTQuetiapine, which is a new atypical antipsychotic agent, was administered at low doses (25–50 mg/day) for psychotic symptoms in eight elderly patients with physical illnesses. Delirium and hallucination were alleviated by the administration of low doses of quetiapine, and the cause–effect relationship between the administration and alleviation of symptoms was evident, particularly in one patient with delirium, because delirium was alleviated after administration began, was exacerbated after discontinuation of quetiapine, and was alleviated again after administration was resumed. Little improvement was observed in delusions or mood disorders. None of the patients showed exacerbation of physical symptoms or abnormalities in clinical laboratory tests. The results of this study suggest that quetiapine might be effective in reducing delirium and hallucination that often accompany physical illness in elderly people and could be used without adverse effects. Received 7 November 2002; accepted 24 December 2002. |